Newsletter

Subscribe and receive updates on this company

Text STOCKS to 72727 for mobile alerts

We are excited to present AVAX Technologies, Inc. (OTC: AVXT).

Full DD Report for AVXT

You must become a subscriber to view this report.


Recent News from (OTC: AVXT)

AVAX Technologies Announces Results Of Its OVAX, Ovarian Cancer Vaccine, Phase 1/2 Clinical Trial In Patients With Relapsed Stage III Or IV Ovarian Cancer.
AVAX Technologies Announces Results Of Its OVAX, Ovarian Cancer Vaccine, Phase 1/2 Clinical Trial In Patients With Relapsed Stage III Or IV Ovarian Cancer.
Source: OTC Markets
Date: January, 22 2016 00:00
AVAX Technologies Announces Participation in Upcoming BIOTECH Showcase 2016
AVAX Technologies Announces Participation in Upcoming BIOTECH Showcase 2016
Source: OTC Markets
Date: December, 14 2015 00:00
AVAX Technologies Inc. Announces the Expansion of its Board of Directors
AVAX Technologies Inc. Announces the Expansion of its Board of Directors
Source: OTC Markets
Date: December, 10 2015 00:00

 


About AVAX Technologies, Inc. (OTC: AVXT)

Logo for AVAX Technologies, Inc. (OTC: AVXT)

Avax Technologies, Inc. is an immuno oncology company focused on developing the next generation of cancer vaccines that maximize antigenicity. Avax is a pioneer in autologous tumor cell vaccines that has developed a vaccine development platform, a proprietary administration regimen and autologous vaccine production process and built a GMP production facility. Avax has late stage cancer vaccines, Ovax and Mvax for ovarian cancer and melanoma, respectively.

 

Contact Information

 

 

Current Management

  • Adele Sommerfeld / CEO
  • Andy Dahl / Chairman
  • Bruno Maruzzo /
  • Serge Morrell /

Current Share Structure

  • Market Cap: $199,648 - 03/16/2018
  • Issue and Outstanding: 142,605,753 - 04/27/2007

 



Daily Technical Chart for (OTC: AVXT)

Daily Technical Chart for (OTC: AVXT)


Stay tuned for daily updates and more on (OTC: AVXT)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (OTC: AVXT)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

OTC Report
@OTCReporter

 

 


Disclaimer: OTC Report publishes reports providing information on selected companies. OTC Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. OTC Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in AVXT is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. OTC Report has received up to $100,000 worth of crypto currency from a non-affiliated third party for the publication and circulation of this report. OTC Report does not own any shares of AVXT and does not buy, sell, or trade any shares of AVXT. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by OTC Report. All rights reserved. Our Full Disclaimer: http://otc.report/disclaimer/